Abstract: Objective  To explore the efficacy and adverse reaction of nedaplatin (NDP) + gemcitabine (GEM) and cisplatin (DDP) + GEM for advanced lung squamous cell carcinoma. Methods  A total of 101 cases advanced untreated patients from September 2012 to December 2013 were randomly divided into 2 groups using random number table method: 69 patients in the observation group accepted NDP+ GEM treatment and 32 patients in the control group received DDP + GEM treatment. The objective response rate (RR), disease control rate (DCR) and progressionfree survival (PFS) and adverse reaction were collected and evaluated. Results  RR was 28.6% (18/63) in the observation group and 15.6% (5/32) in the control group, DCR was 81.0% (51/63) in the observation group and 68.8% (22/32) in the control group (χ²=1.36, P=0.24; χ²=1.67, P=0.20). The median PFS was 4.52 months and 4.01 months in the observation group and control group (χ²=0.09, P=0.73). The major adverse reaction was myelosuppression in both groups (33.3% vs. 37.5%， χ²=0.17， P=0.68). The incidence of ⅢⅣ grade nausea and vomiting was lower in the observation group, compared with the control group (14.5% vs. 56.3%, χ²=19.02, P=0.05). Conclusion  NDP combined with GEM in advanced lung squamous cell carcinoma of the firstline treatment has equivalent efficacy to DDP+GEM, with lower incidence of adverse reaction, which is worthy of further dissemination of research.

Key words: Lung neoplasms, Cisplatin, Nedaplatin, Gemcitabine